INOpulse: Interim Phase II data

Interim data from 20 PAH patients on long-term oxygen therapy in Part 2 of a double-blind, placebo-controlled, crossover, North American Phase II trial showed that 75 ug/kg per hour INOpulse for 8-12 months led to a mean improvement in 6MWD of 31.6 meters compared to baseline. Additionally, 10 patients had a >=50 meter improvement in 6MWD compared to baseline. Furthermore, 11 patients in the 75 ug/kg per hour INOpulse arm who remained on therapy for >=12 hours per day had a mean improvement of 41.6 meters in 6MWD compared to baseline. Part 2 of the trial enrolled 65 PAH patients on >=1 approved PAH therapy to receive 25 or 75 ug/kg per hour INOpulse. ...